Kate Tansey Chevlen
Chief Commercial Officer
Kate Tansey Chevlen, is Chief Commercial Officer at Spyre Therapeutics, where she leads the company’s global commercial strategy as it advances a differentiated pipeline in immunology and inflammation.
Kate is a seasoned biopharma commercial leader with nearly two decades of experience driving strategy, execution, and growth across U.S. and global markets. Prior to joining Spyre, she spent 17 years at Amgen, holding senior leadership roles across marketing, sales, and market access. Her work spanned immunology and inflammation as well as oncology, nephrology, bone, neurology, and cardiovascular disease. Across her career, Kate has played a pivotal role in multiple successful product launches, partnering closely with cross-functional teams to translate scientific innovation into meaningful commercial impact.
Earlier in her career, Kate served as a gubernatorial appointee for the State of California, where she managed healthcare and economic development public policy. She also held roles in local government focused on economic development initiatives.
Kate holds a BA in Politics from Brandeis University, an MBA from the Johnson Graduate School of Management at Cornell University, and a certification in Executive Coaching from the Hudson Institute of Coaching.
